 AstraZeneca PLC LON:AZN announced that Alexions Ultomiris has been recommended for marketing authorisation in the EU for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria PNH. The Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency based its positive opinion on interim results from the Phase III clinical trial in children and teens with PNH. 